Tight glycemic control can be achieved in children following cardiac surgery, but it does not reduce the infection rate, mortality, or length of hospital stay compared to standard care, according to a study published in the September 7 issue of The New England Journal of Medicine
Tight glycemic control can be achieved in children following cardiac surgery, but it does not reduce the infection rate, mortality, or length of hospital stay compared to standard care, according to a study published in the September 7 issue of The New England Journal of Medicine.
The 2-center, prospective, randomized trial, led by Michael S.D. Agus, MD, with Boston Children’s Hospital, consisted of 980 children who were aged 0 through 36 months. The patients were randomly assigned to receive either tight glycemic control or standard care in the cardiac intensive care unit (ICU).
Of the 490 children assigned to tight glycemic control, 444 (91%) received insulin versus 9 (2%) of 490 children who were assigned to standard care.
The researchers found that normal glucose levels were achieved earlier with tight glycemic control than with standard care (6 hours vs 16 hours, P<.001) and were maintained for a greater proportion of the critical illness period (50% vs 33%, P<.001). However, tight glycemic control was not associated with a significantly decreased rate of healthcare–associated infections (8.6 per 1,000 patient-days in the tight glycemic control group compared with 9.9 per 1,000 patient-days in the standard of care group; P=.67). In addition, mortality, length of hospital stay, organ failure, and hypoglycemia rates did not differ significantly between the groups.
“Our trial showed that tight glycemic control targeting a glucose level of 80 to 110 mg per deciliter did not change the rate of healthcare–associated infections, mortality, or length of stay in the cardiac ICU as compared with standard care,” the researchers wrote.
They acknowledged that certain limitations of the trial should be considered, however, and that this group of pediatric patients is unique, so the results “cannot be extrapolated to other pediatric critical care populations.”
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More